SALT LAKE CITY, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (NASDAQ:PRSN) is pleased to announce results of data presented on Sunday, July 12 at the 57th annual American Association of Physicists in Medicine (AAPM) conference, in Anaheim, California. The oral presentation focused on evaluating microwave ablation zone variances based on changes in thermal and electrical properties of tissue.
The study confirms what surgeons have known for a long time – that image-guided percutaneous ablation is already an effective, inexpensive and accessible treatment for liver, lung and kidney tumors. Researchers hypothesized that the technology can be made more effective through better predictive planning and employing a simulation based approach to determine the impact of heterogeneous tissue physical properties on treatment outcome.
Results of the study suggest that variances in tumor and normal tissue blood perfusion significantly affect predicted ablation zone volumes.
"Findings support the use of energy ablation in the treatment of liver, lung and kidney tumors, and suggests that additional data can serve to further enhance the technology as a legitimate treatment option for some cancers," said Clint E. Carnell, President and CEO of Perseon. "Perseon is focused on supportive clinical data for energy ablation in an industry where there is a lack of research and results reporting."
The study was conducted by Rhode Island Hospital, Providence RI, Kansas State University, Manhattan, Kansas and Perseon Corporation, Salt Lake City, Utah. An electromagnetic-thermal finite-element model of Perseon's ST antenna was created for the study.
About Perseon Corporation
Perseon Corporation, formerly BSD Medical Corporation, invests its resources in fighting humanity's worst disease – cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.
Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.
Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Jennifer R. Hoglin Vice President of Global Marketing Phone: (801)972-5555 Email: firstname.lastname@example.org